
QIAGEN N.V. QGEN
Annual report 2024
added 03-14-2026
QIAGEN N.V. Gross Profit 2011-2026 | QGEN
Gross profit is a key indicator of how efficiently a company produces or sells its products. This metric helps assess a business’s ability to generate revenue at the initial stage, before accounting for all other expenses. Regular analysis of gross profit allows companies to respond in a timely manner to changes in cost of goods, pricing strategy, and market conditions.
Calculation formula:Importance for business:
Gross Profit = Revenue – Cost of Goods Sold (COGS)
Revenue — all cash inflows from the sale of goods or services.
Cost of Goods Sold — direct costs related to the production or acquisition of goods:
- Raw materials and supplies
- Wages of production personnel
- Depreciation of equipment
- Transportation and warehousing costs (if directly related to production)
- Assessing core business profitability
If gross profit is declining, it may indicate rising production costs or falling sales. - Financial planning
Gross profit is the basis for calculating other key metrics, such as operating and net profit. - Benchmarking against competitors
Gross profit analysis helps compare the efficiency of different companies within the same industry. - Insights into pricing effectiveness
If gross profit is low, the company may be pricing too low or failing to control costs effectively.
- Increase in raw material and supply costs
- Rising production expenses
- Price reductions due to competition
- Decrease in sales volume
- Currency exchange rate fluctuations (for imports/exports)
Gross profit is an important metric, but it does not provide a complete picture of a company’s financial health, as it does not account for administrative and selling expenses, taxes, debt burden, or depreciation.
Annual Gross Profit QIAGEN N.V.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 967 M | 1.23 B | 1.38 B | 1.45 B | 1.23 B | 1.01 B | 1 B | 923 M | 845 M | 826 M | 865 M | 815 M | 824 M | 750 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.45 B | 750 M | 1.01 B |
Gross Profit of other stocks in the Diagnostics research industry
| Issuer | Gross Profit | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Agilent Technologies
A
|
2.84 B | $ 110.24 | -2.86 % | $ 33.5 B | ||
|
Centogene N.V.
CNTG
|
17.2 M | - | -6.23 % | $ 30.6 M | ||
|
Waters Corporation
WAT
|
1.4 B | $ 289.16 | -3.79 % | $ 17.2 B | ||
|
Exagen
XGN
|
38.8 M | $ 2.68 | -3.94 % | $ 57.8 M | ||
|
Enzo Biochem
ENZ
|
23.2 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
2.26 B | - | - | $ 19.8 B | ||
|
Akumin
AKU
|
53.5 M | - | -17.87 % | $ 25.9 M | ||
|
Burning Rock Biotech Limited
BNR
|
364 M | $ 16.36 | -11.57 % | $ 176 M | ||
|
Sotera Health Company
SHC
|
646 M | $ 13.13 | -3.03 % | $ 3.73 B | ||
|
Heska Corporation
HSKA
|
111 M | - | - | $ 1.31 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
54.4 M | - | - | $ 562 M | ||
|
BioNano Genomics
BNGO
|
2.77 M | $ 1.16 | 0.87 % | $ 6.32 M | ||
|
DermTech
DMTK
|
276 K | - | -11.32 % | $ 2.94 M | ||
|
Aspira Women's Health
AWH
|
4.32 M | - | -6.19 % | $ 10.5 M | ||
|
DexCom
DXCM
|
2.8 B | $ 62.25 | -5.81 % | $ 24.3 B | ||
|
Accelerate Diagnostics
AXDX
|
842 K | - | -61.36 % | $ 2.46 M | ||
|
Global Cord Blood Corporation
CO
|
1.06 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
83.3 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-251 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
281 M | - | 0.12 % | $ 80.1 M | ||
|
HTG Molecular Diagnostics
HTGM
|
4.56 M | - | -20.0 % | $ 1.06 M | ||
|
Castle Biosciences
CSTL
|
53 M | $ 23.53 | -4.74 % | $ 654 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
869 M | - | - | $ 10.7 B | ||
|
Charles River Laboratories International
CRL
|
958 M | $ 159.16 | -3.62 % | $ 7.89 B | ||
|
Quest Diagnostics Incorporated
DGX
|
2.69 B | $ 195.51 | -1.33 % | $ 21.7 B | ||
|
Organovo Holdings
ONVO
|
1.87 M | - | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
366 K | - | -16.95 % | $ 1.54 M | ||
|
Biocept
BIOC
|
6.12 M | - | -13.05 % | $ 7.29 M | ||
|
PerkinElmer
PKI
|
523 M | - | -0.91 % | $ 14.7 B | ||
|
Invitae Corporation
NVTA
|
98.7 M | - | - | $ 21.2 M | ||
|
Interpace Biosciences
IDXG
|
29.9 M | $ 1.68 | -2.89 % | $ 7.37 M | ||
|
Motus GI Holdings
MOTS
|
-398 K | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
421 M | $ 8.7 | -4.92 % | $ 1.89 B | ||
|
Chembio Diagnostics
CEMI
|
6.58 M | - | 0.22 % | $ 16.8 M | ||
|
Laboratory Corporation of America Holdings
LH
|
4.01 B | $ 264.2 | -1.56 % | $ 22 B | ||
|
Psychemedics Corporation
PMD
|
8.41 M | - | -1.84 % | $ 15.3 M | ||
|
Precipio
PRPO
|
6.02 M | $ 25.97 | -4.52 % | $ 33.7 M | ||
|
CareDx, Inc
CDNA
|
81.6 M | $ 16.78 | -3.95 % | $ 894 M | ||
|
Quotient Limited
QTNT
|
23.3 M | - | -11.32 % | $ 1.1 M | ||
|
Syneos Health
SYNH
|
4.42 B | - | - | $ 4.46 B | ||
|
Renalytix AI plc
RNLX
|
156 K | - | 5.66 % | $ 22.7 M | ||
|
Bioventus
BVS
|
388 M | $ 8.94 | -3.46 % | $ 596 M | ||
|
Co-Diagnostics
CODX
|
2.63 M | $ 4.4 | 101.83 % | $ 129 M | ||
|
Meridian Bioscience
VIVO
|
188 M | - | - | $ 1.49 B | ||
|
Danaher Corporation
DHR
|
14.5 B | $ 181.52 | -3.27 % | $ 129 B | ||
|
Surmodics
SRDX
|
33.6 M | - | - | $ 608 M | ||
|
ENDRA Life Sciences
NDRA
|
6.17 K | $ 4.29 | -6.54 % | $ 2.3 M |